Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200041/S009

Scoreflex NC Scoring PTCA Catheter

OrbusNeich Medical (Shenzhen) Co., Ltd. · Decision date Oct 29, 2025

FDA DECISIONP200041/S009

What did the FDA decide?

FDA records P200041/S009 as a supplement to PMA P200041, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 29, 2025.

FDA approval order statement

optimization of manufacturing parameters, adjustments to routine sterility testing and process automation
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 29, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P200041/S009
Regulatory pathway
PMA supplement
Product code
NWX
Decision code
OK30
Decision date
Oct 29, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, percutaneous transluminal coronary angioplasty (ptca), cutting/scoring.

Product code
NWX
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P200041/S009 received

    Application receipt date recorded by FDA.

  2. P200041/S009 · FDA decision

    30-Day Notice

  3. P200041/S005 · Related supplement

    Scoreflex NC Scoring PTCA Catheter

Timeline entries are records held by MedtechLedger for P200041. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200041

Product / regulatory recordCompanyPathwayDecision dateSource
OrbusNeich Medical (Shenzhen) Co., Ltd.PMA supplementJul 31, 2026FDA

Explore the linked device profile

Other records with product code NWX

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

OrbusNeich Medical (Shenzhen) Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
#1 Jinkui Rd., Futian Free Trade Zone, Shenzhen, 518038

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records